These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 28890196

  • 1. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
    Raviotta JM, Smith KJ, DePasse J, Brown ST, Shim E, Nowalk MP, Wateska A, France GS, Zimmerman RK.
    Vaccine; 2017 Oct 09; 35(42):5708-5713. PubMed ID: 28890196
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.
    Raviotta JM, Smith KJ, DePasse J, Brown ST, Shim E, Nowalk MP, Zimmerman RK.
    J Am Geriatr Soc; 2016 Oct 09; 64(10):2126-2131. PubMed ID: 27709600
    [Abstract] [Full Text] [Related]

  • 3. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
    Chit A, Roiz J, Briquet B, Greenberg DP.
    Vaccine; 2015 Jan 29; 33(5):734-41. PubMed ID: 25444791
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
    Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA.
    Hum Vaccin Immunother; 2014 Jan 29; 10(5):1171-80. PubMed ID: 24609063
    [Abstract] [Full Text] [Related]

  • 5. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model.
    Chit A, Roiz J, Aballea S.
    PLoS One; 2015 Jan 29; 10(7):e0133606. PubMed ID: 26222538
    [Abstract] [Full Text] [Related]

  • 6. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
    Boikos C, Fischer L, O'Brien D, Vasey J, Sylvester GC, Mansi JA.
    Clin Infect Dis; 2021 Sep 07; 73(5):816-823. PubMed ID: 33605977
    [Abstract] [Full Text] [Related]

  • 7. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK, QHD00013 Study Group.
    Vaccine; 2019 Sep 16; 37(39):5825-5834. PubMed ID: 31431411
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach.
    Brogan AJ, Talbird SE, Davis AE, Thommes EW, Meier G.
    Hum Vaccin Immunother; 2017 Mar 04; 13(3):533-542. PubMed ID: 27780425
    [Abstract] [Full Text] [Related]

  • 9. Fluzone® High-Dose Influenza Vaccine.
    Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP.
    Expert Rev Vaccines; 2016 Dec 04; 15(12):1495-1505. PubMed ID: 27813430
    [Abstract] [Full Text] [Related]

  • 10. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S, Brzostek J, Meyer I, Donazzolo Y, Leroux-Roels G, Rouzier R, Astruc B, Szymanski H, Toursarkissian N, Vandermeulen C, Kowalska E, Van Damme P, Salamand C, Pepin S.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):596-608. PubMed ID: 28968138
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
    Nowalk MP, Smith KJ, Raviotta JM, Wateska A, Zimmerman RK.
    Vaccine; 2024 Oct 24; 42(24):126107. PubMed ID: 38971665
    [Abstract] [Full Text] [Related]

  • 12. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19.
    Balasubramani GK, Choi WS, Nowalk MP, Zimmerman RK, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Jackson ML, Jackson LA, Chung JR, Spencer S, Fry AM, Patel M, Flannery B, US Flu VE Network Investigators.
    Vaccine; 2020 Sep 29; 38(42):6562-6569. PubMed ID: 32800465
    [Abstract] [Full Text] [Related]

  • 13. High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults.
    Chahine EB.
    Ann Pharmacother; 2021 Jan 29; 55(1):89-97. PubMed ID: 32578447
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017.
    Gaglani M, Vasudevan A, Raiyani C, Murthy K, Chen W, Reis M, Belongia EA, McLean HQ, Jackson ML, Jackson LA, Zimmerman RK, Nowalk MP, Monto AS, Martin ET, Chung JR, Spencer S, Fry AM, Flannery B.
    Clin Infect Dis; 2021 Apr 08; 72(7):1147-1157. PubMed ID: 32006430
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS, Noh JY, Lee J, Choi JY, Lee JS, Kim MS, Kim HS, Bang J, Lavis N, Kim WJ.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):587-592. PubMed ID: 28933625
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
    DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK.
    N Engl J Med; 2014 Aug 14; 371(7):635-45. PubMed ID: 25119609
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, Matassa V, Leong J.
    Vaccine; 2017 Apr 04; 35(15):1856-1864. PubMed ID: 28302411
    [Abstract] [Full Text] [Related]

  • 18. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M.
    Vaccine; 2015 May 15; 33(21):2485-92. PubMed ID: 25843270
    [Abstract] [Full Text] [Related]

  • 19. Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients.
    Manley HJ, Lacson EK, Aweh G, Chen Li N, Weiner DE, Miskulin DC, Hsu CM, Kapoian T, Hayney MS, Meyer KB, Johnson DS.
    Am J Kidney Dis; 2022 Sep 15; 80(3):309-318. PubMed ID: 35288216
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA, Saway W, Gouaux J, Baron M, Baker J, Denis M, Jordanov E, Landolfi V, Yau E.
    Vaccine; 2015 Dec 16; 33(51):7188-7193. PubMed ID: 26555348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.